a. pregnant or breastfeeding women (must be documented by a pregnancy test during hospitalization) b. history of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of the medical record and patient history. c. comfort measures only. d. acute liver disease, or chronic liver disease with a child-pugh score greater than 11. e. resident for more than six months at a skilled nursing facility. f. estimated mortality greater than 50% over the next six months from underlying chronic conditions. g. time since requirement for high flow oxygen or ventilation greater than 5 days. h. anticipated transfer to another hospital which is not a study site within 72 hours. i. patients with either end-stage kidney disease or acute kidney injury who are on dialysis. j. co-enrollment in clinical trials of pharmacologic agents requiring an ind. k. on 3 or more vasopressors. l. pre-existing heart failure with a known left ventricular ejection fraction \<25% or unstable angina pectoris.

a. pregnant or breastfeeding women (must be documented by a pregnancy test during hospitalization) b. history of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of the medical record and patient history. c. comfort measures only. d. acute liver disease, or chronic liver disease with a child-pugh score greater than 11. e. resident for more than six months at a skilled nursing facility. f. estimated mortality greater than 50% over the next six months from underlying chronic conditions. g. time since requirement for high flow oxygen or ventilation greater than 5 days. h. anticipated transfer to another hospital which is not a study site within 72 hours. i. patients with either end-stage kidney disease or acute kidney injury who are on dialysis. j. co-enrollment in clinical trials of pharmacologic agents requiring an ind. k. on 3 or more vasopressors. l. pre-existing heart failure with a known left ventricular ejection fraction \<25% or unstable angina pectoris.

a. pregnant or breastfeeding women (must be documented by a pregnancy test during hospitalization) b. history of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of the medical record and patient history. c. comfort measures only. d. acute liver disease, or chronic liver disease with a child-pugh score greater than 11. e. resident for more than six months at a skilled nursing facility. f. estimated mortality greater than 50% over the next six months from underlying chronic conditions. g. time since requirement for high flow oxygen or ventilation greater than 5 days. h. anticipated transfer to another hospital which is not a study site within 72 hours. i. patients with either end-stage kidney disease or acute kidney injury who are on dialysis. j. co-enrollment in clinical trials of pharmacologic agents requiring an ind. k. on 3 or more vasopressors. l. pre-existing heart failure with a known left ventricular ejection fraction <25% or unstable angina pectoris.

a. pregnant or breastfeeding women (must be documented by a pregnancy test during hospitalization) b. history of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of the medical record and patient history. c. comfort measures only. d. acute liver disease, or chronic liver disease with a child-pugh score greater than 11. e. resident for more than six months at a skilled nursing facility. f. estimated mortality greater than 50% over the next six months from underlying chronic conditions. g. time since requirement for high flow oxygen or ventilation greater than 5 days. h. anticipated transfer to another hospital which is not a study site within 72 hours. i. patients with either end-stage kidney disease or acute kidney injury who are on dialysis. j. co-enrollment in clinical trials of pharmacologic agents requiring an ind. k. on 3 or more vasopressors. l. pre-existing heart failure with a known left ventricular ejection fraction <25% or unstable angina pectoris.

a. pregnant or breastfeeding women (must be documented by a pregnancy test during hospitalization) b. history of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of the medical record and patient history. c. comfort measures only. d. acute liver disease, or chronic liver disease with a child-pugh score greater than 11. e. resident for more than six months at a skilled nursing facility. f. estimated mortality greater than 50% over the next six months from underlying chronic conditions. g. time since requirement for high flow oxygen or ventilation greater than 5 days. h. anticipated transfer to another hospital which is not a study site within 72 hours. i. patients with either end-stage kidney disease or acute kidney injury who are on dialysis. j. co-enrollment in clinical trials of pharmacologic agents requiring an ind k. on 3 or more vasopressors l. pre-existing heart failure with a known left ventricular ejection fraction <25% or unstable angina pectoris

a. pregnant or breastfeeding women (must be documented by a pregnancy test during hospitalization) b. history of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of the medical record and patient history. c. comfort measures only. d. acute liver disease, or chronic liver disease with a child-pugh score greater than 11. e. resident for more than six months at a skilled nursing facility. f. estimated mortality greater than 50% over the next six months from underlying chronic conditions. g. time since requirement for high flow oxygen or ventilation greater than 5 days. h. anticipated transfer to another hospital which is not a study site within 72 hours. i. patients with either end-stage kidney disease or acute kidney injury who are on dialysis. j. co-enrollment in clinical trials of pharmacologic agents requiring an ind k. on 3 or more vasopressors l. pre-existing heart failure with a known left ventricular ejection fraction <25% or unstable angina pectoris

a. pregnant or breastfeeding women. b. history of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of the medical record and patient history. c. comfort measures only. d. acute or chronic liver disease with a child-pugh score greater than 11. e. resident for more than six months at a skilled nursing facility. f. estimated mortality greater than 50% over the next six months from underlying chronic conditions. g. time since requirement for high flow oxygen or ventilation greater than 120 hours (5 days). h. anticipated transfer to another hospital which is not a study site within 72 hours. i. patients with either end-stage kidney disease or acute kidney injury who are on dialysis. j. co-enrollment in clinical trials of pharmacologic agents requiring an ind.

a. pregnant or breastfeeding women. b. history of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of the medical record and patient history. c. comfort measures only. d. acute or chronic liver disease with a child-pugh score greater than 11. e. resident for more than six months at a skilled nursing facility. f. estimated mortality greater than 50% over the next six months from underlying chronic conditions. g. time since requirement for high flow oxygen or ventilation greater than 120 hours (5 days). h. anticipated transfer to another hospital which is not a study site within 72 hours. i. patients with either end-stage kidney disease or acute kidney injury who are on dialysis. j. co-enrollment in clinical trials of pharmacologic agents requiring an ind.

a. pregnant or breastfeeding women. b. history of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of the medical record and patient history. c. comfort measures only. d. acute or chronic liver disease with a child-pugh score greater than 11. e. resident for more than six months at a skilled nursing facility. f. estimated mortality greater than 50% over the next six months from underlying chronic conditions. g. time since requirement for high flow oxygen or ventilation greater than 72 hours. h. anticipated transfer to another hospital which is not a study site within 72 hours.

a. pregnant or breastfeeding women. b. history of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of the medical record and patient history. c. comfort measures only. d. acute or chronic liver disease with a child-pugh score greater than 11. e. resident for more than six months at a skilled nursing facility. f. estimated mortality greater than 50% over the next six months from underlying chronic conditions. g. time since requirement for high flow oxygen or ventilation greater than 72 hours. h. anticipated transfer to another hospital which is not a study site within 72 hours.